204 related articles for article (PubMed ID: 26812792)
1. Free light chain testing for the diagnosis, monitoring and prognostication of AL amyloidosis.
Mollee P; Merlini G
Clin Chem Lab Med; 2016 Jun; 54(6):921-7. PubMed ID: 26812792
[TBL] [Abstract][Full Text] [Related]
2. Serum-free light-chain assay: clinical utility and limitations.
Bhole MV; Sadler R; Ramasamy K
Ann Clin Biochem; 2014 Sep; 51(Pt 5):528-42. PubMed ID: 24489083
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic and prognostic utility of the serum free light chain assay in patients with AL amyloidosis.
Morris KL; Tate JR; Gill D; Kennedy G; Wellwood J; Marlton P; Bird R; Mills AK; Mollee P
Intern Med J; 2007 Jul; 37(7):456-63. PubMed ID: 17547724
[TBL] [Abstract][Full Text] [Related]
4. Identification of amyloidogenic light chains requires the combination of serum-free light chain assay with immunofixation of serum and urine.
Palladini G; Russo P; Bosoni T; Verga L; Sarais G; Lavatelli F; Nuvolone M; Obici L; Casarini S; Donadei S; Albertini R; Righetti G; Marini M; Graziani MS; Melzi D'Eril GV; Moratti R; Merlini G
Clin Chem; 2009 Mar; 55(3):499-504. PubMed ID: 19131635
[TBL] [Abstract][Full Text] [Related]
5. Echocardiographic and biohumoral characteristics in patients with AL and TTR amyloidosis at diagnosis.
Cappelli F; Baldasseroni S; Bergesio F; Perlini S; Salinaro F; Padeletti L; Attanà P; Paoletti Perini A; Moggi Pignone A; Grifoni E; Fabbri A; Marchionni N; Gensini GF; Perfetto F
Clin Cardiol; 2015 Feb; 38(2):69-75. PubMed ID: 25645201
[TBL] [Abstract][Full Text] [Related]
6. Serum-free light-chain analysis in diagnosis and management of multiple myeloma and related conditions.
Milani P; Palladini G; Merlini G
Scand J Clin Lab Invest Suppl; 2016; 245():S113-8. PubMed ID: 27467897
[TBL] [Abstract][Full Text] [Related]
7. Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL.
Palladini G; Lavatelli F; Russo P; Perlini S; Perfetti V; Bosoni T; Obici L; Bradwell AR; D'Eril GM; Fogari R; Moratti R; Merlini G
Blood; 2006 May; 107(10):3854-8. PubMed ID: 16434487
[TBL] [Abstract][Full Text] [Related]
8. Immunoglobulin light chain amyloidosis: 2014 update on diagnosis, prognosis, and treatment.
Gertz MA
Am J Hematol; 2014 Dec; 89(12):1132-40. PubMed ID: 25407896
[TBL] [Abstract][Full Text] [Related]
9. Comparison of Free Light Chain Assays: Freelite and N Latex in Diagnosis, Monitoring, and Predicting Survival in Light Chain Amyloidosis.
Mahmood S; Wassef NL; Salter SJ; Sachchithanantham S; Lane T; Foard D; Whelan CJ; Lachmann HJ; Gillmore JD; Hawkins PN; Wechalekar AD
Am J Clin Pathol; 2016 Jul; 146(1):78-85. PubMed ID: 27353767
[TBL] [Abstract][Full Text] [Related]
10. Sequential cyclophosphamide-bortezomib-dexamethasone unmasks the harmful cardiac effect of dexamethasone in primary light-chain cardiac amyloidosis.
Le Bras F; Molinier-Frenkel V; Guellich A; Dupuis J; Belhadj K; Guendouz S; Ayad K; Colombat M; Benhaiem N; Tissot CM; Hulin A; Jaccard A; Damy T
Eur J Cancer; 2017 May; 76():183-187. PubMed ID: 28334621
[TBL] [Abstract][Full Text] [Related]
11. Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy.
Lachmann HJ; Gallimore R; Gillmore JD; Carr-Smith HD; Bradwell AR; Pepys MB; Hawkins PN
Br J Haematol; 2003 Jul; 122(1):78-84. PubMed ID: 12823348
[TBL] [Abstract][Full Text] [Related]
12. Quantitative analysis of serum free light chains. A new marker for the diagnostic evaluation of primary systemic amyloidosis.
Abraham RS; Katzmann JA; Clark RJ; Bradwell AR; Kyle RA; Gertz MA
Am J Clin Pathol; 2003 Feb; 119(2):274-8. PubMed ID: 12579999
[TBL] [Abstract][Full Text] [Related]
13. Circulating free light chain measurement in the diagnosis, prognostic assessment and evaluation of response of AL amyloidosis: comparison of Freelite and N latex FLC assays.
Palladini G; Jaccard A; Milani P; Lavergne D; Foli A; Bender S; Lavatelli F; Bosoni T; Valentini V; Pirolini L; Ferraro G; Basset M; Russo F; Nuvolone M; Albertini R; Cogne M; Merlini G
Clin Chem Lab Med; 2017 Oct; 55(11):1734-1743. PubMed ID: 28343171
[TBL] [Abstract][Full Text] [Related]
14. [Usefulness of a free light chain immunoassay in serum for the diagnosis and the follow-up of monoclonal gammopathy].
Guenet L; Decaux O; Lechartier H; Ropert M; Grosbois B
Rev Med Interne; 2007 Oct; 28(10):689-97. PubMed ID: 17566612
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the clinical use of midregional pro-atrial natriuretic peptide (MR-proANP) in comparison to N-terminal pro-B-type natriuretic peptide (NT-proBNP) for risk stratification in patients with light-chain amyloidosis.
Kristen AV; Biener M; Hegenbart U; Hardt S; Schnabel PA; Röcken C; Schonland SO; Katus HA; Giannitsis E
Int J Cardiol; 2014 Oct; 176(3):1113-5. PubMed ID: 25115253
[No Abstract] [Full Text] [Related]
16. Light-chain (AL) amyloidosis: diagnosis and treatment.
Sanchorawala V
Clin J Am Soc Nephrol; 2006 Nov; 1(6):1331-41. PubMed ID: 17699366
[TBL] [Abstract][Full Text] [Related]
17. Biochemical markers in early diagnosis and management of systemic amyloidoses.
Lavatelli F; Albertini R; Di Fonzo A; Palladini G; Merlini G
Clin Chem Lab Med; 2014 Nov; 52(11):1517-31. PubMed ID: 24870609
[TBL] [Abstract][Full Text] [Related]
18. Soluble suppression of tumorigenicity 2 (sST2), but not galactin-3, adds to prognostication in patients with systemic AL amyloidosis independent of NT-proBNP and troponin T.
Dispenzieri A; Gertz MA; Saenger A; Kumar SK; Lacy MQ; Buadi FK; Dingli D; Leung N; Zeldenrust S; Hayman SR; Kapoor P; Grogan M; Hwa L; Russell SJ; Go RS; Rajkumar SV; Kyle RA; Jaffe A
Am J Hematol; 2015 Jun; 90(6):524-8. PubMed ID: 25753178
[TBL] [Abstract][Full Text] [Related]
19. Clinical and prognostic significance of serum levels of von Willebrand factor and ADAMTS-13 antigens in AL amyloidosis.
Kastritis E; Papassotiriou I; Terpos E; Roussou M; Gavriatopoulou M; Komitopoulou A; Skevaki C; Eleutherakis-Papaiakovou E; Pamboucas C; Psimenou E; Manios E; Giannouli S; Politou M; Gakiopoulou H; Papadopoulou E; Stamatelopoulos K; Tasidou A; Dimopoulos MA
Blood; 2016 Jul; 128(3):405-9. PubMed ID: 27166361
[TBL] [Abstract][Full Text] [Related]
20. Identification of prognostic markers in transthyretin and AL cardiac amyloidosis.
Damy T; Jaccard A; Guellich A; Lavergne D; Galat A; Deux JF; Hittinger L; Dupuis J; Frenkel V; Rigaud C; Plante-Bordeneuve V; Bodez D; Mohty D
Amyloid; 2016 Sep; 23(3):194-202. PubMed ID: 27647161
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
